About: Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
Creator	Zhang, Chao Xie, Youhua Wu, Yang Yang, Yong Lavillette, Dimitri Yuan, Zhenghong Zhang, Rong Qu, Di Tang, Hong Huang, Zhong Zhou, Yu Sun, Zhiping Gu, Chenjian Bai, Lulu Deng, Qiang Xu, Shiqi Zang, Jinkai Zhang, Xueyang Zhou, Bingjie
Source	BioRxiv
abstract	Recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic. Currently, there is no vaccine available for preventing SARS-CoV-2 infection. Like closely related severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 also uses its receptor-binding domain (RBD) on the spike (S) protein to engage the host receptor, human angiotensin-converting enzyme 2 (ACE2), facilitating subsequent viral entry. Here we report the immunogenicity and vaccine potential of SARS-CoV-2 RBD (SARS2-RBD)-based recombinant proteins. Immunization with SARS2-RBD recombinant proteins potently induced a multi-functional antibody response in mice. The resulting antisera could efficiently block the interaction between SARS2-RBD and ACE2, inhibit S-mediated cell-cell fusion, and neutralize both SARS-CoV-2 pseudovirus entry and authentic SARS-CoV-2 infection. In addition, the anti-RBD sera also exhibited cross binding, ACE2-blockade, and neutralization effects towards SARS-CoV. More importantly, we found that the anti-RBD sera did not promote antibody-dependent enhancement of either SARS-CoV-2 pseudovirus entry or authentic virus infection of Fc receptor-bearing cells. These findings provide a solid foundation for developing RBD-based subunit vaccines for SARS-CoV2.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.1101/2020.05.21.107565
has license	biorxiv
sha1sum (hex)	cb81cff4a1c0ab2639ad1d31667d4eac4130b245
schema:url	https://doi.org/10.1101/2020.05.21.107565
resource representing a document's title	Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
schema:publication	bioRxiv
resource representing a document's body	covid:cb81cff4a1c0ab2639ad1d31667d4eac4130b245#body_text
is schema:about of	named entity 'RBD' named entity 'ACE2' named entity 'interaction' named entity 'efficiently' named entity 'SARS-CoV' named entity 'induced' named entity 'binding' named entity 'solid' named entity 'SARS-CoV-2' named entity 'Immunization' named entity 'domain' named entity 'response' named entity 'RBD' named entity 'human' named entity 'recombinant proteins' named entity 'host' named entity 'fusion' named entity 'antibody-dependent enhancement' named entity 'More' named entity 'authentic' named entity 'SARS-CoV-2' named entity 'domain' named entity 'antibodies' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'SARS-CoV2' named entity 'RBD' named entity 'Immunization' named entity 'pathogen' named entity 'antisera' named entity 'cell fusion' named entity 'RBD' named entity 'recombinant proteins' named entity 'coronavirus disease 2019' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'mice' named entity 'vaccine' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'China' named entity 'THP-1' named entity 'antisera' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'Fudan University' named entity 'RBD' named entity 'RBD' named entity 'viruses' named entity 'antisera' named entity 'Shang' named entity 'SARS-CoV-2' named entity 'fusion protein' named entity 'BALB/c' named entity 'IgG antibody' named entity 'retrovirus' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'cell fusion' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'serum' named entity 'SARS-CoV-2' named entity 'WHO' named entity 'RBD'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software